Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

InflaRx N.V. (IFRX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow InflaRx's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.410 +0.040    +2.92%
16:00:01 - Closed. Currency in USD ( Disclaimer )
After Hours
1.390
-0.020
-1.418%
16:12:49 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 184,265
  • Bid/Ask: 1.350 / 1.430
  • Day's Range: 1.330 - 1.430
InflaRx 1.410 +0.040 +2.92%

InflaRx N.V. Company Profile

 
Get an in-depth profile of InflaRx N.V., including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

62

Equity Type

ORD

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Contact Information

Address Winzerlaer Str. 2
Jena, 07745
Germany
Phone 49 3641 508 180
Fax -

Top Executives

Name Age Since Title
Niels C. Riedemann 49 2007 Co-Founder, CEO & Executive Director
Nicolas Fulpius 47 2007 Independent Chairman of the Board
Renfeng Guo 51 2007 Co-Founder, Chief Scientific Officer & Executive Director
Richard Brudnick 64 2019 Independent Non-Executive Director
K. Reinhart - - Member of Scientific Advisory Board
P. Ward - - Member of Scientific Advisory Board
Mark Christian Kubler 49 2015 Independent Non-Executive Director
Anthony S. Gibney 52 2021 Independent Non-Executive Director
Hege Hellstrom 59 2023 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IFRX Comments

Write your thoughts about InflaRx N.V.
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Edwin Henriquez
Edwin Henriquez Nov 15, 2021 9:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
😳😳😳 why is dropping instead of going up this B....SH 😤
Edwin Henriquez
Edwin Henriquez Nov 12, 2021 3:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
are we do for a short squeeze is going up to fast
Edwin Henriquez
Edwin Henriquez Nov 02, 2021 11:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what just happened 😳 did someone just make a 1 million PUT on this or what why this drop can believe it
Dean Thomas
Dean Thomas Nov 02, 2021 10:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
cross 5 we're gone
Batuhan Babür
Batuhan Babür Oct 28, 2021 9:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Trash
Dean Thomas
Dean Thomas Oct 28, 2021 9:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
trash hahaha I hope you shorted this best of luck your going to need it!!!!!!!!
Val aka
Val aka Oct 14, 2021 11:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1634224450_16997.jpg
Interesting chart...
Val aka
Val aka Oct 08, 2021 1:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Totally undervalued and Q4 promises to be eventful. 1) Covid P3 trial results. 2) AAV P2 trial results. 3) Official funding from German government. 4) Final design of HS P3 study in collaboration with the FDA.
Nick Neri
Nick Neri Sep 08, 2021 1:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Val aka
Val aka Sep 08, 2021 1:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wish it happens as soon as possible
Nick Neri
Nick Neri Aug 09, 2021 9:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buyyyy 2.62
Val aka
Val aka Aug 09, 2021 9:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what is ur pt?
Val aka
Val aka Jun 06, 2021 10:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good stock at 3?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email